From Send2Press® Newswire — Print Friendly Version

Devices and Research News

PRESS RELEASE:

Nuclear Medicine Leader Dr. M. Donald Blaufox Leads Cell

Point Cancer Diagnostic Phase 2/3 Trial
Wed, 10 Feb 2010, 20:02:01 EST

CENTENNIAL, Colo., Feb. 10 (SEND2PRESS NEWSWIRE) -- Cell>Point announced

today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for
its Phase 2/3 clinical trial of 99mTc-EC-G for cancer diagnostic imaging. The trial is
currently underway.

99mTc-EC-G is the company's cancer diagnostic imaging agent, an acronym for

99mTechnetium-EthylenediCysteine-Glucosamine.

"We are honored to have the support and cooperation from a physician with the
recognized stature of Dr. Blaufox," said Greg Colip, Cell>Point CEO. "He's a founder
and leader in nuclear medicine."

Blaufox will present clinical trial findings at select upcoming medical conferences.

Blaufox is founding Chairman of the Department of Nuclear Medicine at Albert Einstein College of Medicine and Montefiore
Medical Center.

Among his many other credentials are:

* Former chairman and lifetime member American Board of Nuclear Medicine
* Principal investigator Hypertension Detection and Follow-up program (Lasker Award recipient)
* Clinical trials review committee National Heart, Lung and Blood Institute
* 293 peer-review articles and chapters
* 25 medical texts
* Editorial board six journals
* Co-editor Seminars in Nuclear Medicine, Yearbook of Nuclear Medicine
* Numerous named lectures and international awards
* Honorary Professor of Medicine, Shanxi University School of Medicine, Taiyuan, China
* Founding chairman Nuclear Medicine Section, New York Academy of Medicine.

Montefiore Medical Center is one of six clinical trial sites for the 99mTc-EC-G cancer trial. Others are John Hopkins University,
Mayo Clinic, Baptist Health South Florida, Decatur Memorial Hospital, and British Columbia Medical Center in North
Vancouver, Canada. Blaufox is also principal investigator of the Montefiore site.

The Phase 2/3 clinical trial compares 99mTc-EC-G (administered and then imaged with a SPECT camera) to 18F-FDG
(administered and then imaged with a PET camera) in the evaluation of patients with non-small cell lung cancer. More
information on the trial can be found at www.clinicaltrials.gov. Trial identifier is NCT00865319.

More information on 99mTc-EC-G can be found at the Cell>Point Website (www.cellpointweb.com) under Technology\Pipeline.

18F-FDG is FluoroDeoxyGlucose. Used in the medical imaging modality Positron Emission Tomography (PET), it is the current
standard in diagnosing, staging, and monitoring treatment of cancers.

SPECT is Single Photon Emission Computed Tomography. SPECT cameras are 25-fold more prevalent than, and one-quarter
the cost of, PET cameras. Radiation from a 99mTc-EC-G SPECT procedure is as much as 75 percent less than that of an 18F-
FDG PET procedure.
About Cell>Point:
Cell>Point is a clinical-stage biopharmaceutical company developing universal molecular imaging agents and molecular
therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart, and other diseases. Cell>Point has
exclusive license to five drug-development platforms, all from The University of Texas M. D. Anderson Cancer Center in
Houston, a world leader in cancer research and care. Information on Cell>Point's drug candidates, recent press releases, and
patents and patent filings can be obtained through its Website at www.cellpointweb.com. The company is headquartered in
Centennial, Colo., and has additional offices in San Francisco and Houston.

NEWS SOURCE: Cell Point LLC

Send2Press® is the originating wire service for this story.

PRESS RELEASE PERMALINK: http://www.send2press.com/newswire/2010-02-0210-004.shtml

For more information about this news release, contact Cell Point LLC directly through their Web site found in the above press release, and NOT
Send2Press.

Copyright © 1983-2010 by Send2Press® Newswire, a unit of Neotrope® (California, USA). All rights reserved.
This "article version" of the above press release may not be republished, broadcast, rewritten, or redistributed without express permission.
www.Send2Press.com PRINTED/READS: 1 times (1 this year)